Savara Inc. declined 1.36% in after-hours trading, following news that Pomerantz Law Firm is investigating claims on behalf of Savara Inc. investors regarding potential securities fraud or other unlawful business practices. The investigation comes after Savara received a refusal to file letter from the FDA for the Biologics License Application of MOLBREEVI.
Comments
No comments yet